Abstract: Disclosed herein are methods of allergen testing and IgG depletion. In some embodiments, testing for IgE antibodies specific for an allergen may be improved by first depleting IgG in a sample. In some embodiments, IgG may be depleted using Biotinylated Protein G (bPG) and streptavidin (SA).

Abstract: A system for forming a deep drawn helmet and method therefor are disclosed. The system includes a forming draw ring and a non-forming draw ring and supports a prepreg stack between a forming aperture of the forming draw ring and a non-forming aperture of the non-forming draw ring. The system clamps a flange portion of the prepreg stack between a contact surface of the forming draw ring and a contact surface of the non-forming draw ring, which forms a clamped assembly of the rings and the prepreg stack. The system then forms a deep drawn helmet preform from the prepreg stack of the clamped assembly. The same system or a different forming system then consolidates one or more of the preforms into a final deep drawn helmet. The system can control sliding of the flange during forming of the helmet preform without reducing the flange clamping force.

Abstract: A method for automatically detecting the data type of data in a column includes receiving a request to import data into a base and determining the data type of the column by applying a set of inferrers to the column. In response to an inferrer returning true, the method selects the data type corresponding to the inferrer as the data type of the column and casts the data in the column to the selected type. A method for importing, converting, and presenting data based on data loss metrics includes receiving a request to import data into a database and determining data loss metrics for each of a set of data types. A user interface is configured to display some of the data types in conjunction with data loss metrics. The method further includes receiving a selection of one of the data types and casting the data to the selected type.

Abstract: Methods, systems, and computer programs are presented for searching and labeling the content of voice conversations. An Engagement Intelligence Platform (EIP) analyzes conversation transcripts to find states and information for each of the states (e.g., interest rate quoted and value of the interest rate). An annotator User Interface (IU) is provided for performing queries, such as, “Find calls were the agent asked the customer for their name and the customer did not answer;” “Find calls where the customer objected after the interest rate for the loan was quoted, “Find calls where the agent asked for consent for recording the call, but no customer confirmation was received.” The EIP analyzes the conversation and labels (e.g., “tags”) the text where the conversation associated with the label took place, such as, “An interest rate was provided.” The labels are customizable, so each client can define its own labels based on business needs.

Abstract: A secure access control system configured to control access to sensitive data stored on disparate systems is disclosed. A first entity is designated to control access to second entity data. An authentication token, generated using a key derivation function, is used to authenticate the first entity. The authenticated first entity is granted access to second entity data. An access control interface is generated configured to selectively grant or withdraw access to second entity data. The access control interface identifies entities associated with respective access controls. The access control interface is instantiated on a first entity device. Activation indications of access controls is received over a network. Access to second entity data is accordingly granted or withdrawn. Access control transition event rules and/or access control transition time rules are retrieved.

Abstract: An apparatus for detecting an analyte, the apparatus includes a biosensor having at least a sensor surface functionalized with a binding ligand, wherein the at least a sensor surface is configured to selectively bind to an analyte, a microfluidic device configured to receive a sample fluid containing the analyte, incubate the biosensor with the sample fluid, and conjugate an anti-analyte molecule with a nanoparticle, wherein the nanoparticle is configured to provide a binding signal to the biosensor when the nanoparticle binds to the analyte bound to the binding ligand on the at least a sensor surface, and incubate the biosensor with the analyte bound to the binding ligand on the at least a sensor surface with the anti-analyte molecule conjugated with the nanoparticle, and a sensor circuit communicatively connected to the biosensor, wherein the sensor circuit is configured to detect at least an analyte characteristic of the analyte.

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

Abstract: This invention relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments in a subject in need thereof. This invention also relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments induced by sleep deprivation and/or insufficient sleep in a subject in need thereof.

Abstract: A risk management system (RMS) device includes a RMS database and a RMS processor. The RMS processor includes a prescriber module to receive a request to enroll a patient in a RMS program of a therapeutic agent associated with multiple indications. The request includes a specification of at least one indication, and a confirmation of a diagnostic test conducted on the patient. The RMS processor also includes a patient module configured to generate a patient profile. The RMS processor also includes a database module configured to store the patient profile in the RMS database. The RMS processor also includes an authorization module configured to generate an authorization code indicating whether the patient is authorized to receive the therapeutic agent. The RMS processor also includes a communication module configured to transmit the authorization code to a pharmacy or a prescriber.

Abstract: A system for facilitating image finding analysis includes one or more processors and one or more hardware storage devices storing instructions that are executable by the one or more processors to configure the system to perform acts such as (i) presenting an image on a user interface, the image being one of a plurality of images provided on the user interface in a navigable format, (ii) obtaining a voice annotation for the image, the voice annotation being based on a voice signal of a user, and (iii) binding the voice annotation to at least one aspect of the image, wherein the binding modifies metadata of the image based on the voice annotation.

Abstract: A method of additively manufacturing an object includes successively forming a plurality of powder layers by depositing powder over a build platform using a powder-deposition apparatus. The method also includes successively forming a binder shell by bonding select regions of each one of the plurality of powder layers before forming each successive one of the plurality of powder layers using a binder-delivery apparatus. The binder shell encloses a portion of the powder. The method further includes densifying the portion of the powder bound by the binder shell using a consolidation apparatus.

Abstract: Embodiments provide swallow-able devices, preparations and methods for delivering therapeutic agents (FAs) within the GI tract such as antibodies (AP-antibodies) or other proteins which neutralize PCSK9 molecules. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations that are configured to be contained within the capsule, advanced from the capsule into the IW and/or peritoneum and degrade to release the TA into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Embodiments are particularly useful for delivery of AP-antibodies and related TA's for the treatment of cholesterol, lipid and related conditions where such TAs are poorly absorbed and/or degraded within the GI tract.

Abstract: Systems, devices, and methods for detaching an implantable device from a delivery system are disclosed herein. One aspect of the present technology, for example, is directed toward an elongated shaft having an inner surface that defines a lumen that extends distally from the proximal portion to an opening at a distal terminus of a distal portion. In some embodiments the distal portion includes an inner polymer structure having a first portion and a second portion positioned distal of the first portion along the length of the inner polymer structure. The first portion can have a first stiffness and the second portion can have a second stiffness less than the first stiffness. The distal portion can further include an outer polymer structure disposed around the inner polymer structure and a coil wound around the inner polymer structure and disposed within the outer polymer structure.

Abstract: The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

Abstract: The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

Abstract: A power system for a vehicle includes a controller that alters an amount of power output from a traction battery according to a magnitude of current passing through a tab of a cell of the traction battery, a temperature, and a distance between a location at which the temperature is measured and the tab.

Abstract: A passively activated switch system for a high-current coil including a plurality of silicon-controlled rectifiers (SCRs) each electrically coupled to a high-current coil, each SCR electrically coupled in parallel to a fast-acting mechanical switch. A passive voltage detector is responsive to an increase in voltage above a predetermined threshold value indicating a start of an over-current event which closes each of the plurality of SCRs to enable a loop current to create a large electromagnetic force. Each fast-acting switch is responsive to the large electromagnetic force and is configured to close to shunt current from each SCR to prevent damage of at least one of the high-current coils or a system that utilizes a high-current coil, or both.

Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Abstract: Techniques provided herein employ a device monitoring service to provide task to content consumption devices that are steaming digital media from the streaming infrastructure. The tasks, when implemented by the content consumption devices, may reveal differences in task performance between authorized devices, which have the authorization to access the digital media, and imposter devices, which exploit vulnerabilities in the streaming pipeline to access the digital media. In addition, the techniques provided herein may include a machine learning/artificial intelligence model that is trained to recognize authorized and imposter content consumption devices based on their task performance.